Skip to main content

Table 4 The 3-year overall and Disease-free survival rates in both groups

From: Initial absolute monocyte count as an immune biomarker for clinical response in acute myeloid leukemia with monocytic differentiation

Groups

Survival rate %

P value

Survival time, months

Mean

Median

Estimate ± SE

95% CI

Estimate ± SE

95% CI

The 3-years OS%

Monocytopenic

0.00%

0.076

11.7 ± 1.4

8.9-14.4

16.3 ± 0

-

Non-monocytopenic

13.40%

9.6 ± 1.5

6.6-12.5

8.5 ± 2.1

4.3–12.7

Overall

0.00%

11.2 ± 1.3

8.6–13.9

10

6.9–13.1

The 3-years DFS%

Monocytopenic

41.70%

0.011

11 ± 0.6

9.8–12.1

12 ± 1.9

8.1–15.7

Non-monocytopenic

0.00%

9 ± 2.5

3.5–13.6

6 ± 1.2

3.5–8.5

Overall

0.00%

12.1 ± 1.5

9–15.1

9.3 ± 1.9

5.5–13.1

  1. OS overall survival, DFS disease-free survival, SE std. error, 95% CI 95% confidence interval, P value of Log rank test